BioSpace News Archive

Immuron Limited is pleased to announce that Ateria Health Australia Pty Ltd, a subsidiary of Ateria Health Limited, has launched Juvia™ in Australia.

Rockwell Medical, Inc. announced that the Company acquired the hemodialysis concentrates business from Evoqua Water Technologies for $11 million up front in cash plus two milestone payments of $2.5 million each at 12- and 24-months from the closing of the transaction.

Vivani Medical, Inc. announced that its wholly-owned subsidiary Cortigent, Inc., a company pioneering neurostimulation to recover critical body function, has completed the fifth year of its Early Feasibility Study of profoundly blind patients implanted with the Orion® Visual Cortical Prosthesis System.

Alzheon, Inc. announced that it will be presenting baseline imaging characteristics from its ongoing APOLLOE4 Phase 3 clinical trial and new correlation analyses from the Phase 2 biomarker study evaluating ALZ-801 oral tablet at the upcoming Alzheimer’s Association International Conference, to be held from July 16 – 20, 2023 in Amsterdam, Netherlands.

Hansa Biopharma, “Hansa”, a pioneer in enzyme technology for rare immunological conditions, announced that the Australian Therapeutic Goods Administration has provisionally approved Idefirix as desensitization treatment for highly sensitized patients prior to kidney transplantation from both living and deceased donors.

NanoViricides, Inc., a leader in the development of highly effective antiviral therapies based on a novel nanomedicines technology, reported on the strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV.

ADC Therapeutics SA announced a voluntary pause in the enrollment of new patients in the Phase 2 LOTIS-9 clinical trial evaluating ZYNLONTA® and rituximab in unfit or frail patients with previously untreated diffuse large B-cell lymphoma.

Synlogic, Inc. announced that the U.S. Food and Drug Administration has granted Fast Track designation to labafenogene marselecobac for the treatment of phenylketonuria.

AccuStem Sciences, Inc., a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, signs further agreement with the IEO, one of the most renowned comprehensive cancer centers in Europe.

Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“ Psyence ” or the “ Company ”) is pleased to announce the appointment of Christopher Bull to the board of directors of the Company effective immediately.